Clever Culture Systems (CC5) AGM 2025 summary

Opening remarks and agenda

• Meeting opened with acknowledgment of traditional custodians and confirmation of quorum.

• Attendees instructed on voting and speaking procedures, with all resolutions to be decided by poll.

• Board, executive team, auditors, and registry representatives introduced.

• Only business listed in the notice of meeting to be addressed.

Financial performance and commercial traction

• Achieved maiden FY25 profit of $1.7 million, driven by $6.6 million in product sales and $1 million in high-margin recurring revenue.

• Cash and current receivables as of September 2025 total $5.5 million.

• Achieved profitability and positive cash flows in FY25, strengthening the balance sheet.

• Blue-chip pharmaceutical customers underpin profit and sales pipeline, with qualified leads estimated at $75 million upfront and $15 million recurring revenue potential.

• 99% of outstanding options exercised, raising AUD 1.1 million and enabling full loan repayment.

Product innovation and pipeline

• APAS® technology automates high-volume environmental monitoring tests, reducing manual labor and compliance risks.

• Launch of contact plates in Q1 FY26 will automate the majority of environmental monitoring tests, expanding the sales pipeline.

• Imaging platform and AI software modules are compatible with multiple hardware configurations, enabling rapid scaling.

• Plans to broaden test offerings and develop a smaller instrument to expand market reach.

• Sales pipeline exceeds 150 instruments, representing over AUD 75 million in potential upfront revenue and up to AUD 15 million in annual recurring revenue.